Canopy Growth Rides Two Waves: Medical Cannabis Deal and US Regulatory Milestone
Published on 07/21/2026 at 01:50 | Redaktion boerse-global.de
Canopy Growth edged higher on Monday, climbing 3.39 percent to €0.8352, as investors weighed a pair of distinct developments — the closing of a transformative Canadian acquisition and the conclusion of a critical phase in the US rescheduling process. The modest gain belies a stock that has lost nearly a fifth of its value since the start of the year and remains more than 58 percent below its December high.
The Canadian cannabis producer has completed its takeover of MTL Cannabis, a deal that management says makes Canopy Growth the largest medical cannabis provider in Canada by revenue. The acquisition is central to a broader strategy that prioritises high-margin brands and vaporizer technology over low-margin commodity biomass. The company has reorganised into two main segments, with an eye toward profitable operations in federally regulated markets worldwide.
On the regulatory front south of the border, the Drug Enforcement Administration has wrapped up its hearings on whether to reclassify recreational cannabis. Witness testimony concluded on July 15, and parties now have until August 17 to submit final comments. An administrative judge will then issue a recommendation — the last formal step before a possible policy shift. A final ruling remains pending, but the timeline is now more tangible for investors.
More immediate financial relief has already arrived for Canopy’s medical business. In April 2026, an executive order reclassified medical cannabis into Schedule III of the US Controlled Substances Act. That change allows the company to deduct ordinary operating expenses such as rent, utilities and marketing under Section 280E of the tax code — a benefit previously denied to cannabis firms. The medical segment generates over C$25 million in revenue, accounting for nearly half of Canopy’s total cannabis sales.
Should investors sell immediately? Or is it worth buying Canopy Growth?
The company also maintains a separate US holding structure, Canopy USA, which sits off the main balance sheet. This arrangement keeps the parent company compliant with exchange listing rules while positioning it for a full market entry when federal laws permit further liberalisation.
Financially, Canopy Growth ended fiscal 2026 with net liquidity of roughly C$131.3 million. The balance sheet has strengthened following recent acquisitions, and the core cannabis business is showing improved operational efficiency — part of a broader restructuring underway across the Canadian industry.
Yet the stock chart tells a volatile story. Monday’s close of €0.8352 sits just 11.36 percent above the 52-week low of €0.75 struck in late March, but a full 14.79 percent below the 200-day moving average of €0.9802. The gap between the current price and the December peak of €2.00 underscores how far the equity has fallen from favour.
Canopy Growth at a turning point? This analysis reveals what investors need to know now.
Investors now have two concrete milestones to watch: the August 17 deadline for DEA comments, and the next quarterly results, which will reveal whether the MTL deal and the tax relief are translating into visible momentum. For a stock that has spent months in a downward spiral, any sign of stabilisation — let alone a sustained recovery — will have to come from one or both of these catalysts delivering on their promise.
Ad
Canopy Growth Stock: New Analysis - 21 July
Fresh Canopy Growth information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
